Castellum, Inc. Announces Record Financial Results
Castellum, Inc. Announces Record Financial Results OTC:ONOV - Revenue for Q3 2021 was a record $7.38 million. Adjusted EBITDA (excluding...
Castellum, Inc. Announces Record Financial Results OTC:ONOV - Revenue for Q3 2021 was a record $7.38 million. Adjusted EBITDA (excluding...
Gross proceeds of $4.75 million at an issue price of $5.25/share with no warrants in a private placement raised from...
Registration trial for CNM-Au8®, a gold nanocrystal suspensionTopline data anticipated 2H 2022World’s first ALS platform trial accelerating the path to...
-- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021--...
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular...
Carson City, Nevada--(Newsfile Corp. - November 15, 2021) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a...
Red Light Holland is continuing its groundbreaking working synergies with Shaman Pharma Corp. and their cGMP laboratory partner, CCrest Laboratories...
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#ASAM--Netsmart, an industry-leading provider of healthcare technology solutions and services, today announced a strategic partnership with the...
BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today provides...
The Butterfly iQ+ is the world’s only single-probe, whole-body, handheld imaging device with the potential to bring medical imaging to...
Selected as Supplier of Infusion Pump Biomedical Services for Leading Global Medical Technology and Diagnostic Equipment Company Worth Expected $14...
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 15, 2021 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the...
Todd Druley, M.D., PhD. brings deep experience of building a medical team and establishing oncology assays, most recently at ArcherDX,...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in Frontiers in Neurology in which...
Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the...
November 14, 2021 Amsterdam, the Netherlands – On June 14, 2021, Royal Philips’ (NYSE: PHG, AEX: PHIA) subsidiary, Philips Respironics,...
Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR)...
BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing...
In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors showed a 25% partial response rate...
- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned...